Carotuximab, referred to as TRC105 or DE-122, represents a unique antibody-drug conjugate construct currently under investigation for treating various oncological illnesses. This particular molecule binds to a specific https://marcfpqp061316.mpeblog.com/73996798/carotuximab-trc105-de-122-a-deep-dive